Autologous bone marrow stem cell transplantation via the hepatic artery for the treatment of hepatitis B virus-related cirrhosis: a PRISMA-compliant meta-analysis based on the Chinese population

Abstract

Objective: Autologous bone marrow stem cell (ABMSC) transplantation has been considered a promising option for hepatitis B virus-related cirrhosis (HBV-C). Although an analysis of the published literature has been performed, the exact effects and safety have yet to be systematically investigated. Methods: We conducted a wide-ranging online search of electronic databases (Web of Science, PubMed, Cochrane Library, Embase, CNKI, VIP, and Wanfang database) to reach systematic conclusions. Outcome measurements, including therapeutic efficacy, clinical symptoms, and adverse events, were extracted and analyzed statistically. Results: Ultimately, a total of 10 articles including 662 HBV-C patients were included in this analysis, which indicated that ABMSC therapy could significantly improve liver function in patients with HBV-C in terms of the MELD and Child-Pugh scores, total bilirubin, serum albumin, alanine aminotransferase, aspartate aminotransferase, and coagulation function. Compared with patients receiving routine therapy (RT), those treated with ABMSC and RT combined therapy showed improved clinical symptoms, as represented by increased appetite and reduced fatigue and ascitic fluid and abdominal distension. Moreover, the fibrosis indexes indicated a reduction in liver fibrosis in patients treated with combined therapy according to the improved levels of hyaluronic acid (MD = − 70.47, CI = − 103.72-37.21, P < 0.0001), laminin (MD = − 25.11, CI = − 37.73-12.49, P < 0.0001), type III procollagen (MD = − 22.42, CI = − 34.49-10.34, P = 0.0003), and type IV collagen (MD = − 22.50, CI = − 39.92-5.08, P = 0.01). No obvious adverse events occurred during ABMSC treatment. Conclusion: ABMSC transplantation via the hepatic artery was safe and effective in treating HBV-C without causing severe adverse events.

Regenerative Effect of Mesenteric Fat Stem Cells on ccl4-Induced Liver Cirrhosis

“…All previous studies have been used stem cells derived from bone marrow (15,20), umbilical cord (21) the liver itself (22) or hepatic cell line (23) and the amniotic membrane (16), but in this study we used mesenteric adipose tissue to harvest stem cells and applied a modi ed technique which proved good results clinically and histopathologically. Few animal studies administered adipose stem cells (ADSC) for hepatic regeneration with different methods (24,25).…”

Effect of Liuweiwuling tablet on biochemical and virological parameters, and quality of life in patients with hepatitis B virus-related cirrhosis

“…[ 1 – 5 ] There are over 350 million people with chronic hepatitis B worldwide, and hepatitis B virus (HBV) infection is one of the main causes of LC and hepatocellular carcinoma (HCC). [ 6 , 7 ] More than one million HBV carriers die of LC and HCC every year. [ 7 ] As reported by the World Health Organization, 45% of the population lives in high-prevalence chronic hepatitis B areas.…”

“…[ 6 , 7 ] More than one million HBV carriers die of LC and HCC every year. [ 7 ] As reported by the World Health Organization, 45% of the population lives in high-prevalence chronic hepatitis B areas. [ 7 , 8 ] Among untreated chronic hepatitis B patients, 8% to 20% develop to cirrhosis in 5 years.…”

“…[ 7 ] As reported by the World Health Organization, 45% of the population lives in high-prevalence chronic hepatitis B areas. [ 7 , 8 ] Among untreated chronic hepatitis B patients, 8% to 20% develop to cirrhosis in 5 years. [ 7 , 9 , 10 ] Meanwhile, untreated decompensated cirrhosis patients show a poor prognosis, with a 5-year survival rate ranging from 14% to 35%.…”

“…[ 7 , 8 ] Among untreated chronic hepatitis B patients, 8% to 20% develop to cirrhosis in 5 years. [ 7 , 9 , 10 ] Meanwhile, untreated decompensated cirrhosis patients show a poor prognosis, with a 5-year survival rate ranging from 14% to 35%. [ 7 , 9 , 10 ]…”